PSNL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.00% compare to its pairs and should correct upwards.

Stats
Šios dienos apimtis	125 339
Vidutinė apimtis	227 887
Rinkos kapitalizacija	60.77M
EPS	$-0.260 ( Q1 \| 2024-05-08 )
Kita pelno data	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.620 (Sector) 42.63 (Industry) 0
ATR14	$0.00500 (0.43%)

ACRS -0.90%

AKU -17.87%

APDN -0.73%

BDSX 2.00%

BIOC 0.00%

BNGO -7.69%

BNR 1.05%

CDNA 7.92%

CEMI 0.22%

CHEK -0.99%

CNTG -3.80%

CSTL 2.88%

DMTK -11.32%

DRIO 1.71%

EXAS -5.03%

FLDM -7.02%

FLGT -2.39%

GENE 1.35%

GH -0.59%

GTH 0.12%

HTGM 0.00%

ICLR 0.08%

IDXX -1.37%

ILMN -1.95%

ISPC -1.87%

LAB 0.00%

LMDX 0.00%

MDXH 0.84%

ME -7.58%

MEDP -2.94%

MYGN 0.62%

MYNZ -14.13%

NDRA -5.73%

NEO 3.97%

NEOG -2.07%

NOTV -4.05%

NTRA -1.56%

OCDX 0.92%

OLK 0.75%

OPGN 0.39%

OPK -0.79%

PMD 2.11%

PRPO 4.85%

PSNL -3.31%

RDNT 0.03%

SERA 3.50%

SHC -0.25%

SQL 0.00%

STIM -1.10%

STRR 2.71%

STRRP 8.67%

SYNH 0.02%

TRIB 2.90%

TTOO -1.66%

TWST 3.79%

VIVO 0.00%

XGN -1.62%

Insider Trading

Date	Person	Action	Amount	type
2024-06-17	Chen Richard	Sell	5 055	Common Stock
2024-06-17	Tachibana Aaron	Sell	7 176	Common Stock
2024-06-17	Moore Stephen Michael	Sell	1 585	Common Stock
2024-05-17	Myers Woodrow A Jr	Buy	50 000	Stock Option (right to buy)
2024-05-17	Shoff Lonnie	Buy	50 000	Stock Option (right to buy)

INSIDER POWER
-59.44
Last 98 transactions
Buy: 4 067 705 \| Sell: 9 658 662

Koreliacija (AI algo v.1.1b): Undervalued: 0.00% $1.170 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: 0.11 (neutral)

Trumpas: -0.82 (strong negative)

Signal:(41.026) Neutral

Personalis Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
EXFY	0.819

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Personalis Inc Koreliacija - Valiuta/Žaliavos

0.42
( neutral )

0.41
( neutral )

0.00
( neutral )

0.10
( neutral )

0.00
( neutral )

-0.60
( weak negative )

Personalis Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$73.48M
Bruto pelnas:	$18.21M (24.78 %)
EPS:	$-2.25

FY	2023
Pajamos:	$73.48M
Bruto pelnas:	$18.21M (24.78 %)
EPS:	$-2.25

FY	2022
Pajamos:	$65.05M
Bruto pelnas:	$13.35M (20.52 %)
EPS:	$-2.48

FY	2021
Pajamos:	$85.49M
Bruto pelnas:	$31.66M (37.03 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Personalis Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Personalis Inc

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.